CD34 and neoplasm: At the end of the experiment (week 16), all lungs were dissected and immunohistochemically analyzed to assess and quantify the microscopic effects of combined therapies with or without temsirolimus on general tumor characteristics (H&E stain; Ki-67 and CD34) and to identify possible mechanisms for the observed differences in growth inhibition.